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The effects of haploidentical rhG-CSF-mobilized blood and marrow transplantation (HBMT) on hematological malignances are
well established. Previous prospective single-center studies have demonstrated better survival after HBMT versus haploidentical
rhG-CSF-mobilized peripheral blood stem cell transplantation (HPBSCT) for acute leukemia (AL) not in remission (NR) or in
more than the second complete remission (>CR2). To test the hypothesis that HBMT is still superior to HPBSCT for patients with
AL, multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) in CR1/CR2 and for patients with chronic myeloid leukemia
in the first and second chronic phase lacking a matched donor, we designed a propensity score method-based multicenter study.
Hematopoietic recovery, acute graft-versus-host disease (aGVHD), and chronic GVHD were comparable between the HBMT
group (n=168) and theHPBSCT group (n=42). No significant differences were found in non-relapsemortality rate (20.17%±3.58%
and 27.24%±7.16%, P=0.18) or relapse rate (19.96%±3.72% and 28.49%±8.25%, P=0.32) between the HBMT group and the
HPBSCT group. HBMT recipients had better overall survival (65.0%±4.2% and 54.2%±8.3%, P=0.037) and disease-free survival
(59.9%±4.6% and 44.3%±8.7%, P=0.051). Multivariate analysis showed that HPBSCT was associated with poorer DFS (HR
(95%CI), 1.639 (0.995–2.699), P=0.052). Our comparisons showed that HBMT was superior to HPBSCT as a post-remission
treatment for patients lacking an identical donor.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is a potentially curative treatment for hemato-
logical malignancies and blood diseases. With advancements
in the field of haploidentical allo-HSCT (haplo-HSCT) in the
last decade, including a new transplantation model (Apperley
et al., 2016; Aversa et al., 2005; Bashey et al., 2013; Di
Bartolomeo et al., 2013; Huang et al., 2006; Raiola et al.,
2013; Solomon et al., 2012), haplo-HSCT would be practical
for patients lacking an HLA-matched sibling or unrelated
donor. To perform HSC grafts for haplo-HSCT, some cen-
ters use bone marrow (BM) grafts, and some centers use
G-CSF-mobilized BM (GBM) or G-CSF-mobilized PBSCs
(GPBs). Over the past 15 years, by using a combination of
GBM and GPBs, as well as antithymocyte globulin (ATG)
administration for the prophylaxis of graft-versus-host dis-
ease (GVHD) and graft rejection, the Beijing group initiated
one of the earliest clinical trials to explore unmanipulated
myeloablative haploidentical blood and marrow transplan-
tation (HBMT) for leukemia (Huang et al., 2006; Lv and
Huang, 2015). However, which type of grafts would be best
for haplo-HSCT is still unknown. The use of GBM grafts in
comparison with BM or GPB grafts in allo-HSCT from HLA
identical sibling donors (ISDs) is either better or similar
(Chang and Huang, 2011; Pessach et al., 2015). The use
of the combination of GBM and GPB grafts in comparison
with GPB grafts in allo-HSCT from ISDs demonstrated that
GVHD incidence was significantly lower, and neutrophil
and platelet engraftment were faster, making overall survival
(OS) superior in the group with a combination of GBM
and GPB (Zhao et al., 2013). However, the above results
obtained with transplants from HLA-identical siblings or
unrelated donors may not be applicable to transplants from
haploidentical donors, given the greater genetic diversity in
the haploidentical recipient.
Our previous single-center studies have demonstrated
better survival after HBMT compared to haploidentical GPB
allo-HSCT (HPBSCT) for high-risk acute leukemia (AL)
(not in remission (NR) or in more than the second complete
remission (>CR2)) (Xu et al., 2010). Which procedure is
the optimal HSC graft for standard-risk hematological ma-
lignances (AL, multiple myeloma (MM), and non-Hodgkin
lymphomas (NHL) in CR1/CR2 and patients with chronic
myeloid leukemia (CML) in the first and second chronic
phase (CP1/CP2)) remains unknown. It would be hard to
perform a randomized study on standard-risk patients using
haplo-HSCT. Recently, the propensity score approach has
been widely used, and it has been proposed to mimic a
clinical trial. The propensity score approach can be used to
produce an unbiased comparison of the treatment effect under
some nonrandomized conditions. To test the hypothesis that
HBMT is superior to HPBSCT as a post-remission therapy
for patients with standard-risk hematological malignances
who lack a matched donor, we designed a multicenter study
comparing HPBSCT vs. propensity score method-matched
HBMT. Our comparisons showed that HBMT was superior
as a post-remission treatment for hematological malignances
in patients lacking an identical donor.
RESULTS
Neutrophil and platelet engraftment
The neutrophil engraftments occurred at 13 days (range,
8–32 days) for the HBMT recipients and at 13 days (range,
9–25 days) for the HPBSCT recipients. The 100-day cu-
mulative incidence (±SE) of neutrophil engraftment in
the haplo-HSCT group was comparable (HBMT group,
99.4%±0.06%; HPBSCT group, 92.9%±4.0%, P=0.328).
The platelet engraftments occurred at 22 days (range, 7–220
days) and 16 days (range, 8–40 days) for the HBMT and
HPBSCT recipients, respectively. The 100-day cumulative
incidence (±SE) of platelet engraftment in the HBMT group
was comparable to the HPBSCT group (HBMT group,
92.86%±2.29%; HPBSCT group, 90.48%±4.89%, P=0.74).
GVHD
The 100-day cumulative incidence (±SE) of grade I–IV acute
GVHD (aGVHD), grade II–IV aGVHD and grade III–IV
aGVHD was comparable between the two groups (I–IV
aGVHD, HBMT group: 58.33%±3.82% vs. HPBSCT group:
45.24%±7.81%, P=0.22; II–IV aGVHD, HBMT group:
33.33%±3.7% vs. HPBSCT group: 28.57%±7.07%, P=0.71;
III–IV aGVHD, HBMT group: 7.74%±2.07% vs. HPBSCT
group: 2.38%±2.38%, P=0.21; Figure 1A–C, respectively).
A total of 158 patients in the HBMT group and 38 patients
in the HPBSCT group survived longer than 100 days after
HSCT and suffered from chronic GVHD. The cumula-
tive incidence (±SE) of total chronic GVHD or extensive
chronic GVHD in the HBMT group was comparable to
that in the HPBSCT group (total chronic GVHD: HBMT
group, 50.83%±4.01%, HPBSCT group, 56.14%±8.41%,
P=0.62, Figure 1D; extensive chronic GVHD: HBMT group,
19.11%±3.15%, HPBSCT group, 13.38%±5.69%, P=0.42,
Figure 1E).
Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and
invasive fungal infection (IFI)
At day 100 after HSCT, the cumulative incidence
(±SE) of CMV antigenemia was 66.02%±3.82% vs.
73.81%±7.0% for the HBMT group versus the HPBSCT
group (P=0.49) (Figure 2A). The cumulative incidence
(±SE) of CMV-related disease was comparable between the
two groups (HBMT group, 2.56%±1.27%, HPBSCT group,
7.14%±4.0%, P=0.24).
At  day  100  after HSCT, the cumulative incidence (±SE)
of EBV  viremia  was  8.3%±2.5%  and  2.5%±2.5%  in  the
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Figure 1   The acute and chronic GVHD occurrence between the HBMT group and the HPBSCT group. A, Grade I-IV acute GVHD; B, grade II-IV acute
GVHD; C, grade III-IV acute GVHD; D, overall chronic GVHD; E, extensive chronic GVHD.
Figure 2   Infection with CMV and invasive fungi (IFI) between the HBMT group and the HPBSCT group. A, CMV viremia; B, invasive fungal infection (IFI).
HBMT and HPBSCT groups, respectively (P=0.18), and
the cumulative incidence of EBV-associated post-transplant
lymphoproliferative disorder (PTLD) was 2.38%±1.18%
vs. 2.45%±2.45% in the HBMT group versus the HPBSCT
group (P=0.99). The cumulative incidence (±SE) of IFI
was 14.58%±2.88% vs. 19.12%±6.17% in the HBMT group
versus the HPBSCT group, respectively (P=0.46, Figure
2B).
Relapse and non-relapse mortality (NRM)
The cumulative incidence (±SE) of relapse for the HBMT and
HPBSCT groups was 19.96%±3.72% and 28.49%±8.25%,
respectively (P=0.32) (Figure 3A). At the time of last fol-
low-up, 39 patients were in relapse, and 30 patients had died
of relapse, including 23 in the HBMT group and seven in the
HPBSCT group, with a median time to death of 12.7 months
(range,  3.7–36.9)  and  10.7   months   (range,   4.73–16.8)
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Figure 3    Clinical outcomes between the HBMT group and the HPBSCT group. A, Relapse; B, non-relapse mortality; C, overall survival; D, disease-free
survival; E, overall survival; F, disease-free survival.
after HSCT, respectively. The cumulative incidence (±SE) of
NRM for the HBMT andHPBSCT groups was 20.17%±3.6%
and 27.24%±7.16%, respectively (P=0.18) (Figure 3B).
Overall survival (OS) and disease-free survival (DFS)
The percentages (±SE) of OS in the HBMT and HPBSCT
groups were 65.0%±4.2% and 54.2%±8.3%, respectively
(P=0.037) (Figure 3C). The probabilities (±SE) of DFS in
the HBMT and HPBSCT groups were 59.9%±4.6% and
44.3%±8.7%, respectively (P=0.051) (Figure 3D). The
probabilities of OS and DFS in the CR1/CP1 group were
significantly higher than those in the CR2/CP2 group (OS,
65.3%±4.0% and 52.0%±9.0%, respectively, P=0.034;
DFS, 58.3%±4.5% and 49.5%±9.0%, respectively, P=0.034,
Figure 3E and F). Risk factor analysis is shown in Table 1.
CR2/CP2 was associated with poorer OS (HR 1.759, 95%CI
0.993–3.116, P=0.053), and HPBSCT was associated with
poorer DFS (HR 1.639, 95%CI 0.995–2.699, P=0.052).
The median follow-up of survivors was 1,304 days (range;
202–3,226 days).
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Figure 4   Immune reconstitution between the HBMT group and the HPBSCT group. Absolute numbers of (A) CD19+ B cells, (B) CD3+ T cells, (C) CD4+ T
cells, and (D) CD8+ T cells; the percentage of (E) CD4+CD25+ T cells, (F) CD4+CD45RA+ T cells, and (G) CD4+CD45RO+ T cells among the CD3+ T cells; the
percentage of (H) CD4+CD28+ T cells among the CD4+ T cells; the percentage of (I) CD8+CD28+ T cells among the CD8+ T cells.
Table 1    Multivariate analysis
Outcome and factors HR (95% CI) P-value
OS
risk(CR2/CP2 vs. CR1/CP1) 1.759 (0.993–3.116) 0.053
DFS
HPBSCT vs. HBMT 1.639 (0.995–2.699) 0.052
The percentages (±SE) of OS in the HBMT and HPB-
SCT groups for CR1/CP1 patients were 67.1%±4.6% and
55.9%±8.6% (P=0.023), respectively, and for CR2/CP2 pa-
tients they were 53.8%±9.8% and 33.3%±22.5% (P=0.895),
respectively. The percentages (±SE) of DFS in the
HBMT and HPBSCT groups for CR1/CP1 patients were
61.8%±5.1% and 45.1%±9.1% (P=0.020), respectively,
and for CR2/CP2 patients they were 50.0%±9.8% and
33.3%±25.5% (P=0.894), respectively.
Immune reconstitution
Immune recovery after transplantation was assessed between
January 2006 andMay 2008 on days 30, 60, 90–120, 180, and
360 based on lymphocyte immunophenotyping. There were
a total of 13 patients in the HPBSCT group and 19 matched
patients in the HBMT group with complete sets of immuno-
logical data. As shown in Figure 4, there were no differences
in the following measurements between the two groups: the
absolute number of the CD3+, CD4+ or CD8+ T cells; the
percentage of CD4–CD8–, CD8+CD28+, or CD4+CD28+ cells
among the CD3+ T cells; or the percentage of CD4+CD45RA+
or CD4+CD45RO+ cells among the CD4+ T cells. However,
Zhao, X., et al.   Sci China Life Sci   November (2016)  Vol. 59  No. 11 1143
the absolute number of CD19+ cells was higher in the HPB-
SCT group at day 60 compared to the HBMT group (P=0.04,
Figure 4A). The expression of CD25+ on CD4+ cells had a
trend toward being higher in the HBMT group at day 30 com-
pared to the HPBSCT group (Figure 4E, P=0.087).
DISCUSSION
This multicenter, propensity score-matched study showed a
significant survival difference between transplant recipients
who received GPB and those who received the mixture of
GBM and GPB from haploidentical donors. The results
were similar among recipients with CR1/CP1 or CR2/CP2,
although the lack of significant differences in CR2/CP2
patients was probably due to the limited number of patients.
Other transplantation outcomes, including acute GVHD,
chronic GVHD, CMV viremia, CMV disease, EBV viremia,
IFI, relapse rates, and non-relapse mortality were comparable
in the HBMT group compared to the HPBSCT group.
This is the first study to compare the clinical outcomes of
standard-risk patients who underwent HBMTwith those who
underwent HPBSCT. We focused on standard-risk patients
because they should be more comparable in terms of recipient
characteristics between the HBMT and HPBSCT groups, in
comparison to previous retrospective cohort studies. Mean-
while, all the patients underwent a uniform conditioning reg-
imen as well as GVHD prophylaxis, except for the different
stem cell source. Therefore, for all standard-risk patients, the
use of the mixture of GBM and GPBs should increase the
length of overall survival.
In accordance with our previous report (Xu et al., 2010;
Zhao et al., 2013), there were trends of lower NRM and re-
lapse rate in theGBM/GPBmixed stem cell source group than
in the GPB graft group. Therefore, the GBM/GPBmixed har-
vest was superior to GPB in terms of overall survival in stan-
dard-risk patients. Meanwhile, although there was no signif-
icant difference, the HBMT group tended to have faster neu-
trophil engraftment than the HPBSCT group, in accordance
with our previous report (Xu et al., 2010) (Zhao et al., 2013).
In accordance with HLA-matched ISDs (Zhao et al.,
2013), acute GVHD was comparable between the HBMT
group and the HPBSCT group in this study of standard-risk
post-haplo-HSCT patients. However, one study reported
more grade II-IV acute GVHD in the HPBSCT group than
in the HBMT group in high-risk patients after haplo-HSCT
(Xu et al., 2010). Based on our previous study using our
haploidentical transplantation, matching the relationship
of patients to donors (mother donors are associated with
higher GVHD) and donor characteristics should influence
the GVHD occurrence (Wang et al., 2014a, b). In this
study, donor-patient relationships were comparable between
groups. However, because of the small sample sizes, there
have been significant differences in donor-patient relation-
ships as well as the number of HLA locus mismatches in
the previous high-risk cohort, which could affect the acute
GVHD occurrence (Xu et al., 2010).
No significant differences were found in immune reconsti-
tution between the HBMT group and the HPBSCT group in
this study, except that the HPBSCT group had faster CD19+
B cell recovery at day 60, and the HBMT group had a higher
frequency of CD4+CD25+ T cells at day 30. It would be hard
to clarify their clear clinical significance based on our small
sample size. Further studies should be performed on the rela-
tionship between stem cell source composition and immune
reconstitution.
Only two retrospective studies have explored the effect
of GPB graft or BM graft on haploidentical transplantation.
Bradstock et al. compared outcomes for two retrospective
cohorts of patients undergoing reduced-intensity condi-
tioning therapy transplantation from haploidentical related
donors and receiving post-transplant prophylaxis against
GVHD with high-dose cyclophosphamide (Cy), tacrolimus,
and mycophenolate. They demonstrated that the use of GPBs
for haploidentical RIC transplants is a feasible strategy with
equivalent rates of acute and chronic GVHD, equivalent risk
of relapse, and lower non-relapse mortality compared to BM
(Bradstock et al., 2015). Castagna et al. also retrospectively
analyzed the use of BM versus GPBs in a cohort of patients
receiving haploidentical T cell-replete transplantation after a
non-myeloablative conditioning regimen with post-infusion
Cy. They found that the engraftment, GVHD, relapse, NRM
and survival were similar in the two groups. Therefore, GPBs
could be a valid alternative to BM after transplantation from
a haploidentical donor using post-infusion Cy (Castagna et
al., 2014).
Many approaches have been developed or are currently
being designed to improve transplant outcomes of HBMT,
such as investigating the optimal dose of ATG (Wang et al.,
2014b), selecting the best donor (Wang et al., 2014a) and us-
ing mDLI (Huang et al., 2007, 2008a, b, 2009; Wang et al.,
2012) to reduce relapse. Therefore, the HBMT protocol has
been one of the most commonly used haploidentical trans-
plant protocols and has come to be known as the “Beijing
protocol” (Apperley et al., 2016; Wang et al., 2013). It of-
fers rapid immune recovery (Chang et al., 2014), desirable
health-related quality of life and comparable survival rate to
HLA-identical sibling transplantation (Mo et al., 2012, 2013)
or HLA-matched unrelated donor transplantation (Xiao-Jun
et al., 2009). The Beijing protocol also shows superiority in
treating pediatric hematological malignancies compared with
umbilical cord blood transplantation and could be success-
fully used as a post-remission treatment algorithm for adults
with acute myeloid leukemia and unfavorable cytogenetics
(Mo et al., 2014). Based on the current study, as well as
our previous study (Xu et al., 2010), GBM/GPB mixed stem
cells show superiority in overall survival compared to GPB
1144 Zhao, X., et al.   Sci China Life Sci   November (2016)  Vol. 59  No. 11
stem cells for haplo-HSCT, suggesting that the combination
of GBM and GPB as the source of stem cells contributes to
the clinical efficacy of the Beijing Protocol.
A limitation of our study could be that, even though well
matched, the groups were not well balanced for number of
patients (168 vs. 42) and that this prevented us from reaching
significance in the statistical analysis of NRM and relapse.
In fact, NRM and relapse incidence were slightly higher in
HPBSCT (cumulative incidence of relapse: HPBSCT 28%
vs. HBMT 19.9%; NRM: HPBSCT 27% vs. HBMT 20.1%),
although not significantly. Meanwhile, donor preference may
affect the choice of stem cell source. Donors who declined
to donate bone marrow were put into the HPBSCT group.
Therefore, donor preference was a bias of this study, although
we used the propensity score-matched patients’ characteris-
tics and multiple centers to keep this bias to a minimum. We
need to perform a well-designed, prospective, randomized
trial in the future to confirm this conclusion.
In conclusion, our comparisons showed that HBMTwas su-
perior to HPBSCT as a post-remission treatment for patients
lacking an identical donor. The encouraging overall survival
experienced in the HBMT cohort provides a rationale for fur-
ther exploring this strategy in future prospective clinical trials
to collect data from the national bone marrow registration of
China and to compare the stem cell source (GBM/GPBmixed




Eligible patients were those who lacked a suitable matched
related donor. A total of 1,488 patients with AML, ALL,
CML, MM, or NHL receiving either a HBMT (n=1,431) or
a HPBSCT from a family donor (n=57) between January
2002 and December 2014 from three centers in China were
enrolled. We performed a matched-pair comparison of the
HBMT group with a subset of closely matched HPBSCT
patients selected based on propensity score matching. The
clinical outcomes were compared in HBMT (n=168) and
HPBSCT patients (n=42) after they were matched using
propensity score analysis. Table 2 summarizes the de-
mographic and clinical characteristics of the standard-risk
patients after propensity score-matched analysis in this study.
Patients’ clinical outcomes were reported to the Peking
University Institute of Hematology by the three centers.
Informed consent was obtained from all of the patients. The
study protocol was approved by the ethics committee of
Peking University People’s Hospital.
Transplant regimen
The major preconditioning consisted of cytarabine (4 g m–2
day–1, –10 to –9 days), busulfan (BU, 4 mg kg–1 day–1 admin-
istered orally on days –8 to –6 before January 2008 or 3.2 mg
kg–1 day–1 administered intravenously on days –8 to –6 after
January 2008), cyclophosphamide (CY, 1.8 g m–2 day–1, –5
to –4 days), simustine (250 mg m–2, –3 days), and rabbit an-
tithymocyte globulin (ATG; thymoglobulin, 2.5 mg kg–1, –5
to –2 days; Sanofi, France). All of the haplo-HSCT recip-
ients received cyclosporine A, mycophenolate mofetil, and
short-term methotrexate for GVHD prophylaxis. The criteria
for choosing HBMT or HPBSCT were based on local proto-
col and donor preference. HBMT was suggested by the local
protocol, but if the donors declined to donate bone marrow,
the patients were put into the HPBSCT group. The prevention
and surveillance of infections at our institute have previously
been described in detail (Huang et al., 2006). The diagnosis
of GVHD was in accordance with the common international
criteria (Filipovich et al., 2005; Przepiorka et al., 1995).
HLA typing and stem cell harvesting
HLA typing and stem cell harvesting were previously de-
scribed in detail3. Donors were primed with rhG-CSF (Fil-
grastim, Kirin, Japan; 5 mg kg–1 per day) injected s.c. for five
to six consecutive days. In the HPBSCT group, on the fourth
and fifth day (and on the sixth day if needed), GPBs were
collected using a COBE Blood Cell Separator (Spectra LRS,
COBE BCT Inc., USA) at a rate of 80 mL min–1 from a total
blood volume of 150–200 mL kg–1. The fresh and unmanipu-
lated GPBs were infused into the recipient on the day of col-
lection. All donor-recipient pairs were typed at the HLA-A,
B, and DR loci at our institute. To determine HLA-A and
HLA-B status, low-resolution DNA techniques were used.
High-resolution techniques were used for HLA-DRB1 typ-
ing. Each patient with haplo-HSCT received stem cells from
a family member who shared the one HLA haplotype with
the patient but differed to varying degrees for the HLA-A, B,
and D antigens of the haplotype, which were not shared. In
addition to typing each donor-recipient pair, HLA typing was
performed on parents and offspring only for analysis, to guar-
antee true haploid genetic background.
Definition and assessments
Standard-risk patients were defined as patients with AML,
ALL, NHL, or MM in CR1/CR2 and patients with CML in
CP1/CP2. Neutrophil engraftment was defined as the first
day of an absolute neutrophil count (ANC) of 0.5×109 L–1
or more for three consecutive days, and platelet engraftment
was defined as the first day of a platelet count of 20×109
L–1 or more for seven consecutive days without transfusion.
Chronic GVHD was evaluated in patients who survived for
more than 100 days and had a sustained engraftment. OS was
defined as time from transplantation to death from any cause.
DFS was defined as survival in continuous CR. Relapse was
defined as morphological evidence of the disease in the pe-
ripheral blood, bone marrow, or extramedullary sites. NRM
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Acute myeloid leukemia (AML) 66 (39.3%) 14 (33.4%)
Acute lymphoblastic leukemia (ALL) 64 (38.1%) 14 (33.3%)
Chronic myeloid leukemia (CML) 32 (19%) 13 (31%)
Multiple myeloma (MM) 1 (0.6%) 0 (0%)
Non-Hodgkin lymphomas (NHL) 5 (3.0%) 1 (2.4%)
Disease risk before transplantation 0.43
CR1/CP1 142 (84.5%) 35 (83.3%)
CR2/CP2 26 (15.5%) 7 (16.7%)
Patient age (median, range) 26 (3–57) 36 (28–44)
Donor age (median, range) 33 (13–54) 37 (26–48)
Donor-recipient relationship—no. (%) 0.652
Male-male 53 (32%) 11 (26%)
Male-female 21 (13%) 8 (19%)
Female-male 60 (36%) 16 (38%)
Female-female 34 (20%) 7 (17%)
Donor-recipient relationship—no. (%) 0.584
Father-child 42 (25%) 5 (11.9%)
Mother-child 35 (20.8%) 9 (21.4%)
Child-parent 22 (13.1%) 3 (7.1%)
Sibling-sibling 68 (40.5%) 23 (54.8%)
Cousin-cousin 5 (0.6%) 1 (2.4%)
Anunt or uncle-nephew 0 (0%) 1 (2.4%)
Conditioning regimen—no. (%)
Busulfan+cyclophosphamide 168 (100%) 42 (100%)
GVHD prophylaxis—no. (%)
ATG+cyclosporine+methotrexate 168 (100%) 42 (100%)
No. of donor mismatches at HLA-A, B, and DRB1—no./total no. (%) 0.517
0 1 (0.6%) 1 (2.4%)
1 11 (6.5%) 1 (2.4%)
2 55 (32.7%) 13 (31.0%)
3 101 (60.1%) 27 (64.3%)
CD34+ cell dose per kilogram (×106)
Median (range) 2.03 (0.52–9.77) 2.46 (1.68–3.25) 0.901
CD3+ cell dose per kilogram (×108)
Median (range) 1.50 (0.12–5.44) 2.28 (2.05–2.51) <0.001
was defined as death after HSCT without disease progression
or relapse.
Endpoints
The primary endpoint of comparison was OS. Secondary
endpoints were hematopoietic recovery, CMV, EBV, inva-
sive fungal infection (IFI), acute GVHD (grade I–IV, II–IV
and III–IV), chronic GVHD (overall and extensive), NRM,
relapse and DFS.
Immune reconstitution
Flow cytometry analysis was performed using a four-color
flow cytometer (Becton-Dickinson, American). Immune re-
constitution was analyzed using three sets of 4-color anti-
body panels: CD45-PerCP, CD3-APC, CD4-FITC, CD8-PE;
CD4-PerCP, CD25-PE, CD45RO-APC, CD45RA-FITC; and
CD10-PE, CD19-APC, CD45-PerCP, and CD34-FITC (Bec-
ton-Dickinson, USA). Fifty thousand PBMCs were collected
per sample and analyzed using Cell Quest software (Bec-
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ton-Dickinson). Fluorochrome-conjugated isotype-matched
nonspecific mAbs were used as negative controls for each as-
say.
Propensity score calculation
We calculated the propensity score matching in R using the
Match It package with nearest-neighbor 1-to-4 matching
(R Development Core Team (2006)); R, A language and
environment for statistical computing. R Foundation for Sta-
tistical Computing, Vienna, Austria. ISBN: 3-900051-07-0,
URL: http://www.R-project.org). Factors included in the
propensity score were as follows: patient age and donor age
at HSCT as a continuous variable; patient sex and donor
sex (male/female) as an indicator variable; year of trans-
plantation as a continuous variable; performance status at
transplantation as an ordinal variable; risk status (CR1/CP1,
CR2/CP2) as an indicator variable; relationship of patient to
donor (father, mother, child, sibling, cousin, aunt or uncle)
as an indicator variable; and diagnosis (AML, ALL, CML,
NHL, MM) as an indicator variable. We utilized as many
variables as possible in the propensity score to reduce or
eliminate the effect of treatment selection bias.
Statistical analysis
Patient characteristics and therapeutic outcomes were com-
pared between the HBMT and HPBSCT groups. Data were
censored at the time of last available follow-up. OS and DFS
were estimated using the Kaplan-Meier method. Compet-
ing risk analysis was used to calculate the cumulative inci-
dence of engraftments, GVHD, CMV, infection with EBV
or invasive fungus, relapse, and NRM using the Gray test to
test for differences between the HBMT and HPBSCT groups.
Death without engraftment was the competing event for en-
graftment, death without GVHD was the competing event
for GVHD, and death without infection was the competing
event for infection. For NRM, relapse was the competing
event; for relapse, NRM was the competing event. The fi-
nal multivariate models were built using a forward stepwise
model selection approach with a 5% significance level. Fi-
nal models for each outcome were reported. The end point
of the last follow-up for all survivors was May 1, 2015. Im-
mune reconstitution was compared between the HBMT and
HPBSCT groups using the Wilcoxon rank-sum test. Data
were primarily analyzed using the SPSS software package
(SPSS Inc., USA). The R software package (version 2.6.1;
http://www.r-project.org) was used for competing risk analy-
sis.
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